Remix Therapeutics, a biotechnology company in the clinical stage, is pioneering the development of small molecule therapies targeting RNA processing to combat the root causes of diseases. Today, they announced a significant step forward with the enrollment and dosing of the first patients in two Phase 1 clinical trials for REM-422. This innovative compound, a MYB mRNA degrader, holds promise as a potential treatment for recurrent or metastatic adenoid cystic carcinoma (ACC) and acute myeloid leukemia/high-risk myelodysplastic syndromes (AML/MDS). Moreover, REM-422 has been granted Orphan Drug Designation by the FDA for these indications.

Remix, expressed enthusiasm about advancing REM-422 into clinical trials. He highlighted the initial safety and pharmacokinetics data in patients, emphasizing their commitment to exploring REM-422's potential in targeting MYB, an oncogenic transcription factor previously considered difficult to target.

The Phase 1 trials, which are open-label and multicenter, aim to assess REM-422's safety, pharmacokinetics/pharmacodynamics (PK/PD), and anti-tumor activity in patients with recurrent or metastatic ACC and those with relapsed/refractory AML or high-risk MDS. These trials comprise both a Dose Escalation Phase and a Dose Expansion Phase.

MYB is implicated in several solid tumors and hematological malignancies, including ACC and AML. REM-422, as a potent and selective small molecule mRNA degrader, effectively reduces MYB mRNA and subsequent protein expression, exhibiting anti-tumor activity in MYB-dependent tumor models.

Remix, emphasized the critical need for effective treatments for metastatic ACC. He underscored REM-422's potential as a targeted therapy addressing MYB dysregulation, a key driver of ACC. Additionally, he expressed anticipation about assessing REM-422's safety and efficacy in AML and high-risk MDS, where MYB plays a crucial role in leukemogenesis.

Orphan Drug Designation by the U.S. FDA signifies the recognition of REM-422 as a potential therapy for rare medical conditions affecting fewer than 200,000 individuals in the United States.

ACC is a rare cancer primarily found in glandular tissues in the head and neck, often associated with MYB protein overexpression. Current treatment options include surgery, radiation, and chemotherapy. AML is a common form of acute leukemia in adults, characterized by genetic mutations in bone marrow cells leading to the overproduction of leukemic white blood cells. MDS represents a group of disorders affecting blood-forming units in the bone marrow, with high-risk cases often progressing to AML. Despite existing treatments for AML, there remains a significant unmet need, particularly in patients who relapse after initial response.

 

Source: prnewswire.com

Report Abuse